The expanded number of therapies with varying mechanisms of action for type 2 diabetes has resulted in novel combination regimens for patients not achieving goals despite therapy with metformin. Dr. Serge Jabbour will review novel combinations and approaches to intensifying therapy in this interactive case study.
Diabetes continues to have a significant impact on morbidity and mortality in the United States, and is an ongoing treatment challenge for primary care providers who lack confidence with treatment intensification including newer agents and combination therapies resulting in clinical inertia. Further, approaches to improved adherence and lifestyle modification through shared-decision making continue to evolve with the goal of improving quality of care.
In this interactive case study, Dr. Richard Pratley, Medical Director of the Florida Diabetes Institute, walks through the clinical decision-making process for a 60-year-old African American woman with type 2 diabetes whose diabetes is progressing despite metformin therapy. Dr. Pratley examines factors likely contributing to this patient's poor glycemic control, as well as steps for intensification of therapy beyond metformin and considerations for treatment selection, such as risk for hypoglycemia and cardiovascular issues.
In this case presentation, Kathleen Wyne, MD, PhD, Associate Professor of Clinical Internal Medicine, Division of Endocrinology, Diabetes, and Metabolism at The Ohio State University College of Medicine shares strategies for intensification of diabetes management that incorporate real life patient challenges with evidence based medicine to develop a regimen that is likely to attain the patient’s A1C target. These strategies include working with what the patient is actually willing to do while trying to attain A1C target, with consideration to importance of controlling both fasting and postprandial glucose in patients with type 2 diabetes, and the use of GLP-1 receptor agonists in combination with basal insulin for optimal glycemic control in patients who require intensification of therapy.
With an ever-increasing array of oral and injectable treatment options available for management of patients with type 2 diabetes mellitus (T2DM) at all stages of the disease, it is more challenging than ever for clinicians to appropriately select and titrate antihyperglycemic agents. In this case compendium, Vivian Fonseca, MD, Professor of Medicine and Pharmacology and Chief, Section of Endocrinology at Tulane University Health Sciences Center, New Orleans, presents three patient cases at different stages of T2DM in order to illustrate how clinicians can set treatment goals, select therapies, monitor response, and intensify therapy in both the newly diagnosed patient and one with long-standing disease and multiple comorbidities.
This activity reviews the latest data on the safety and efficacy of GLP-1 receptor agonists in the management of type 2 diabetes mellitus, utilizing case presentations to illustrate the application of theory to practice and incorporating the practical recommendations of leading clinicians in the treatment of these challenging patients.
This enduring CME multimedia webcast activity captured at the 2014 Primary Care Updates will highlight incorporating the new AACE comprehensive diabetes management algorithm into clinical practice, addressing post-prandial hyperglycemia in patients taking basal insulin and address safety and patient concerns with insulin therapy.
The aim of this program is to examine the cardiovascular effects of pharmacotherapies used in managing type 2 diabetes with a focus on key clinical trials regarding the use of diabetes medications in patients with established or at elevated risk for cardiovascular disease.
The aim of this program is to review the impact of diabetes on eye health and how glycemic control contributes to diabetic eye disease. This program will also review treatment for diabetic eye disease and review referral and follow up plans for patients with diabetes to an appropriate eye specialist.
Primary care clinicians in the Southern United States face unique challenges in preventing and managing patients with T2DM. In this session, esteemed faulty will lend valuable insights into early screening and identification of those with pre-diabetes and T2DM in diverse patient populations, including minorities and the elderly. Earlier diagnosis offers the potential for reducing the risk for the development and progression of diabetes and associated complications.